Alkermes (ALKS)
(Delayed Data from NSDQ)
$27.32 USD
-0.31 (-1.12%)
Updated Jul 31, 2024 04:00 PM ET
After-Market: $27.30 -0.02 (-0.07%) 6:04 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Brokerage Reports
0 items in cart
Alkermes plc [ALKS]
Reports for Purchase
Showing records 121 - 140 ( 291 total )
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Renewed Focus on Profitability Underwhelms for 2020; We Stay at Neutral, Nudge Target Down to $25 from $26
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Perspectives from KOL Dinner on Major Depressive Disorder
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Is ALKS an Earnings Story Now? Reiterate Neutral, Lower Target to $26
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Is Evolution Enough? Vumerity Hits Primary Endpoint in EVOLVE-MS-2
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Vivitrol Settlement Settles Nerves After Mixed 2Q
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D